Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
FluMist maker announces plan to achieve $2 billion in revenues by 2009
April 6th, 2004
MedImmune, Inc., (MEDI) announced that it expects to achieve $2 billion in total revenues by 2009, driven by investments in its pipeline and the continued growth of its currently marketed products. MedImmune also announced results from two phase III studies showing the refrigerator-stable formulation of FluMist (Influenza Virus Vaccine Live, Intranasal) was statistically significantly more effective than the injectable influenza vaccine in preventing culture-confirmed influenza. These data reaffirmed MedImmune's commitment to developing and commercializing FluMist. If successful, MedImmune expects peak annual FluMist sales in excess of $500 million in the U.S. and...
Source: Cancer Weekly (2004-04-06)
|
